内容摘要：The authority has spent £8.2m on new heating and insulation systems at seven libraries, six fire stations and a day centre.

The authority has spent £8.2m on new heating and insulation systems at seven libraries, six fire stations and a day centre.

The woman, who uses the name Kate Elysia, said she was raped by Mohammed Ali Sultan when she was 18 and that he also arranged for other men to rape her.Sultan was jailed for seven years in 2012 after admitting having sex with two teenage girls, one of whom was 13 years old, his sentence was extended in 2015 and again in 2019 when he was found guilty of further sexual offences.

The Ministry of Justice apologised for failing to inform Ms Elysia of a parole hearing.Ms Elysia, who waived her right to anonymity, told the BBC's Newsnight programme: "He would regularly bring around other people, who would rape me at my house and I think he was selling my address, because people would turn up to my house who I didn't know."She also said she was given alcohol and drugs by Sultan and said he was a "very dangerous man".

A parole board decided in December he could be released back into the community, but Ms Elysia said: "I had no idea that he was even up for parole, so at first I was a bit taken aback and didn't really know what to do."She said her first instinct was to tell no-one, but she changed her mind and decided to tell her family "just in case something happened after he's released".

"I was scared for me and I was scared for my family," she said.

The Ministry of Justice said: "We offer our deepest apologies to Kate Elysia for failing to inform her of the hearing.But she hopes to stay alive until her children, both in their early 20s, leave home.

Jeannie is one of about 1,000 people who can’t access a treatment that could extend their lives because it has not been approved for funding on the NHS in England, Wales and Northern Ireland.The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average.

The health assessment body, NICE, is the only organisation around the world so far to say no to the drug for this condition. It says that it is too expensive for the NHS to fund.The decision applies in England - but Wales and Northern Ireland will follow this guidance too.